64 results
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
of any sanctions administered or enforced by the United States Government (including, without limitation, the U.S. Department of the Treasury’s Office … of Foreign Assets Control, or the U.S. Department of State), the United Nations Security Council, the European Union, His Majesty’s Treasury, or other
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
agreement. See "—Material Agreements—Licensing Agreement for Leflutrozole".
Government Regulation
Among others, the FDA, U.S. Department of Health … permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
or political subdivision, department or agency of a government;
“Phase II” means a human clinical trial of a Product in any country that would satisfy … , exemption of, or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an insider trading investigation conducted either by the U.S. Securities and Exchange Commission (the “SEC”) or the U.S. Department of Justice, even
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
to the Nasdaq Capital Market. On May 8, 2023, the Company received notification from the Nasdaq Listings Qualifications Department that the ADSs had
6-K
EX-99.1
ljbaj jh63adrtg6d
8 May 23
Current report (foreign)
4:07pm
6-K
rf71wnhl9
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
i5vpwnr6d8gn h9
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
7gtrj4 vwkbnn8
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
u0a2ox nweqle30784
2 Nov 22
Current report (foreign)
4:17pm
6-K
ziw8n9ouz sepa9f2
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.1
43a9b9km9 3o
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.2
1q2gptifx60ahw12sit
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
bgzk9 rkc76
5 Jul 22
Current report (foreign)
4:15pm
6-K
pkxtcdt
25 May 22
Current report (foreign)
4:11pm